Medtronic to Acquire CathWorks for Up to $585M, Expanding AI-Driven Cardiovascular Diagnostics
Event summary
- Medtronic will acquire CathWorks for up to $585M, including potential earn-outs, following a 2022 strategic partnership.
- The deal aims to bolster Medtronic's interventional cardiology portfolio with CathWorks' AI-driven FFRangio System.
- Pending FTC clearance, the acquisition is expected to close by the end of Medtronic's fiscal year 2026.
- CathWorks' FFRangio System uses AI and computational science to provide comprehensive coronary physiology assessments from routine angiograms.
The big picture
Medtronic's acquisition of CathWorks underscores the growing trend of AI-driven diagnostics in cardiovascular care, aiming to disrupt the traditional wire-based FFR segment. The deal reflects Medtronic's strategy to expand its interventional cardiology portfolio through targeted acquisitions, leveraging data and AI to transform cath lab procedures. With a deal size of up to $585M, this acquisition positions Medtronic to potentially set new standards in coronary physiology assessments.
What we're watching
- Regulatory Approval
- Whether the FTC will clear the acquisition by the end of Medtronic's fiscal year 2026.
- Integration Challenges
- How Medtronic will integrate CathWorks' technology into its existing cardiovascular portfolio.
- Market Expansion
- The pace at which Medtronic can expand the commercial reach of the FFRangio System globally.
Related topics